Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Gemcitabine vs Docetaxel + Capecitabine in Advanced Breast Cancer
NCT00191438Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival. Started Oct 2002; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191438.